Literature DB >> 19838662

[Vaccination and multiple sclerosis].

M Löbermann1, A Winkelmann, E C Reisinger, U K Zettl.   

Abstract

Vaccinations to prevent communicable diseases are, like in other chronic diseases, of special importance in patients with multiple sclerosis (MS). Various bacterial and viral infections have been shown to induce relapses of MS. Reports of possible adverse effects of vaccinations on the course of multiple sclerosis have led patients and treating physicians to exercise caution in the use of vaccines. A number of vaccines have been studied with respect to the risk in MS patients. Some vaccines, for example against yellow fever, are not indicated in MS due to the risk of MS exacerbation. In contrast, tetanus or hepatitis B vaccines do not represent a risk for manifestation or disease progression of MS. Before and during immunomodulatory therapy of MS special attention should be given to adequate protection against vaccine preventable diseases.This paper reviews the indications and specific side effects of vaccinations in MS patients. Additionally, issues of vaccination under immunomodulatory therapy of MS are discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19838662     DOI: 10.1007/s00115-009-2865-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  83 in total

1.  Virus, liver and autoimmunity.

Authors:  D P Bogdanos; G Mieli-Vergani; D Vergani
Journal:  Dig Liver Dis       Date:  2000 Jun-Jul       Impact factor: 4.088

2.  INFECTION AND IMMUNIZATION IN MULTIPLE SCLEROSIS.

Authors:  W A SIBLEY; J M FOLEY
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

3.  The risk of relapses in multiple sclerosis during systemic infections.

Authors:  Jorge Correale; Marcela Fiol; Wendy Gilmore
Journal:  Neurology       Date:  2006-07-26       Impact factor: 9.910

4.  School-based hepatitis B vaccination programme and adolescent multiple sclerosis.

Authors:  A D Sadovnick; D W Scheifele
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

5.  Influenza virus vaccination of patients with multiple sclerosis.

Authors:  F Mokhtarian; D Shirazian; L Morgante; A Miller; D Grob; E Lichstein
Journal:  Mult Scler       Date:  1997-08       Impact factor: 6.312

6.  Vaccinations and risk of central nervous system demyelinating diseases in adults.

Authors:  Frank DeStefano; Thomas Verstraeten; Lisa A Jackson; Catherine A Okoro; Patti Benson; Steven B Black; Henry R Shinefield; John P Mullooly; William Likosky; Robert T Chen
Journal:  Arch Neurol       Date:  2003-04

7.  Rituximab treatment results in impaired secondary humoral immune responsiveness.

Authors:  Lizet E van der Kolk; Joke W Baars; Martin H Prins; Marinus H J van Oers
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis.

Authors:  J De Keyser; C Zwanikken; M Boon
Journal:  J Neurol Sci       Date:  1998-07-15       Impact factor: 3.181

9.  Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults.

Authors:  Pierre Van Damme; Gianmaria Minervini; Charles L Liss; Barbara McCarson; Timo Vesikari; John W Boslego; Prakash K Bhuyan
Journal:  Hum Vaccin       Date:  2009-02-14

10.  Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.

Authors:  James G Krueger; Hans D Ochs; Piyush Patel; Ellen Gilkerson; Emma Guttman-Yassky; Wolfgang Dummer
Journal:  J Invest Dermatol       Date:  2008-05-22       Impact factor: 8.551

View more
  4 in total

Review 1.  [Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Authors:  M Löbermann; B Handorn; A Winkelmann; E C Reisinger; H P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2018-10       Impact factor: 1.214

Review 2.  [Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation].

Authors:  Alexander Winkelmann; Micha Löbermann; Uwe K Zettl
Journal:  Nervenarzt       Date:  2019-12       Impact factor: 1.214

3.  [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2012-02       Impact factor: 1.214

Review 4.  Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

Authors:  Celia Oreja-Guevara; Heinz Wiendl; Bernd C Kieseier; Laura Airas
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.